OTCPK:MNTM

Stock Analysis Report

Executive Summary

Mount TAM Biotechnologies, Inc., a biopharmaceutical company, engages in the development of bio-pharmaceuticals to treat autoimmune diseases in the United States.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Share Price & News

How has Mount TAM Biotechnologies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.1%

MNTM

3.1%

US Biotechs

1.8%

US Market


1 Year Return

-81.3%

MNTM

-7.9%

US Biotechs

7.3%

US Market

Return vs Industry: MNTM underperformed the US Biotechs industry which returned -7.9% over the past year.

Return vs Market: MNTM underperformed the US Market which returned 7.3% over the past year.


Shareholder returns

MNTMIndustryMarket
7 Day-1.1%3.1%1.8%
30 Day-64.0%-2.4%-0.7%
90 Day-64.3%-0.8%0.06%
1 Year-81.3%-81.3%-7.1%-7.9%9.7%7.3%
3 Year-98.0%-98.0%14.2%10.3%46.3%36.9%
5 Yearn/a0.07%-4.8%64.5%46.5%

Price Volatility Vs. Market

How volatile is Mount TAM Biotechnologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Mount TAM Biotechnologies undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Mount TAM Biotechnologies is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Mount TAM Biotechnologies has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of MNTM’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Mount TAM Biotechnologies regulatory filings here.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Mount TAM Biotechnologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mount TAM Biotechnologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Mount TAM Biotechnologies performed over the past 5 years?

-5.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: MNTM is unprofitable, and losses have increased over the past 5 years at a rate of -5.3% per year.

Accelerating Growth: Unable to compare MNTM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MNTM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: MNTM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: MNTM is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: MNTM is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Mount TAM Biotechnologies's financial position?


Financial Position Analysis

Short Term Liabilities: MNTM has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: MNTM has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: MNTM has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: MNTM's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: MNTM has a low level of unsold assets or inventory.

Debt Coverage by Assets: MNTM has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MNTM has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MNTM has less than a year of cash runway if free cash flow continues to grow at historical rates of 3.2% each year.


Next Steps

Dividend

What is Mount TAM Biotechnologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.7%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate MNTM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MNTM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if MNTM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MNTM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MNTM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Mount TAM Biotechnologies's salary, the management and board of directors tenure and is there insider trading?

3.6yrs

Average management tenure


CEO

Richard Marshak (60yo)

3.6yrs

Tenure

US$907,733

Compensation

Dr. Richard Marshak, VMD, MBA, has been Chief Executive Officer at Mount TAM Biotechnologies, Inc. since March 29, 2016 and serves as its Director. Dr. Marshak has 18 years of pharmaceutical experience acr ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Richard's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Richard's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

3.6yrs

Average Tenure

56yo

Average Age

Experienced Management: MNTM's management team is considered experienced (3.6 years average tenure).


Board Age and Tenure

4.0yrs

Average Tenure

56yo

Average Age

Experienced Board: MNTM's board of directors are considered experienced (4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Jim Stapleton (56yo)

    CFO, Treasurer & Secretary

    • Tenure: 3.4yrs
    • Compensation: US$276.83k
  • Chester Aldridge (48yo)

    Co-Founder & Director

    • Tenure: 5.8yrs
  • Richard Marshak (60yo)

    CEO & Director

    • Tenure: 3.6yrs
    • Compensation: US$907.73k

Board Members

  • Chester Aldridge (48yo)

    Co-Founder & Director

    • Tenure: 5.8yrs
  • Brian Kennedy (52yo)

    Chairman of the Board

    • Tenure: 4yrs
  • Richard Marshak (60yo)

    CEO & Director

    • Tenure: 3.6yrs
    • Compensation: US$907.73k
  • Jim Farrell (63yo)

    Director

    • Tenure: 1.3yrs

Company Information

Mount TAM Biotechnologies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Mount TAM Biotechnologies, Inc.
  • Ticker: MNTM
  • Exchange: OTCPK
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$501.396k
  • Shares outstanding: 55.71m
  • Website: https://www.mounttambiotech.com

Number of Employees


Location

  • Mount TAM Biotechnologies, Inc.
  • 106 Main Street
  • Suite 4E
  • Burlington
  • Vermont
  • 5401
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MNTMOTCPK (Pink Sheets LLC)YesNew Common StockUSUSDAug 2015

Biography

Mount TAM Biotechnologies, Inc., a biopharmaceutical company, engages in the development of bio-pharmaceuticals to treat autoimmune diseases in the United States. The company’s lead product candidate is TA ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 00:37
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.